Inhibition of nuclear factor kappa B transcription activity drives a synergistic effect of pyrrolidine dithiocarbamate and cisplatin for treatment of renal cell carcinoma

Apoptosis

Volumn 15, Issue 4, 2010, Pages 412-425

  Morais, Christudas ^a,b   Gobe, Glenda ^b   Johnson, David W ^b   Healy, Helen ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Apoptosis; Bcl 2; Bcl XL; Multi drug resistance; Nuclear factor kappa B; Renal cell carcinoma

Indexed keywords

CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PROTEIN BCL 2; PROTEIN BCL XL; PYRROLIDINE DITHIOCARBAMATE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; GENE EXPRESSION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; KIDNEY CARCINOMA; PRIORITY JOURNAL; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; BCL-X PROTEIN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; KIDNEY NEOPLASMS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NF-KAPPA B; P-GLYCOPROTEIN; PROTEIN SUBUNITS; PYRROLIDINES; THIOCARBAMATES; TRANSCRIPTION, GENETIC;

EID: 77951667799     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-009-0414-y     Document Type: Article

References (63)

1. KL Weber M Doucet JE Price C Baker SJ Kim IJ Fidler 2003 Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice Cancer Res 63 2940 2947 12782601 1:CAS:528:DC%2BD3sXkt1ait7s%3D (Pubitemid 36667167)
2. RH Weiss PY Lin 2006 Kidney cancer: identification of novel targets for therapy Kidney Int 69 224 232 10.1038/sj.ki.5000065 16408110 1:CAS:528:DC%2BD28XksVKqtg%3D%3D (Pubitemid 43323071)
3. G Keller AV Schally A Nagy G Halmos B Baker JB Engel 2005 Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas Cancer 104 2266 2274 10.1002/cncr.21402 16211544 1:CAS:528:DC%2BD2MXht1Cksr7N (Pubitemid 41579974)
4. MM Gottesman I Pastan 1993 Biochemistry of multidrug resistance mediated by the multidrug transporter Annu Rev Biochem 62 385 427 10.1146/annurev.bi.62. 070193.002125 8102521 1:CAS:528:DyaK3sXlsFWnsbY%3D (Pubitemid 23237876)
5. G Zhou MT Kuo 1997 NF-kappaB-mediated induction of mdr1b expression by insulin in rat hepatoma cells J Biol Chem 272 15174 15183 10.1074/jbc.272.24. 15174 9182539 1:CAS:528:DyaK2sXjvFOntbo%3D (Pubitemid 27255533)
6. AT Fojo DW Shen LA Mickley I Pastan MM Gottesman 1987 Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene J Clin Oncol 5 1922 1927 3681376 1:CAS:528: DyaL1cXht1Cisb8%3D (Pubitemid 18010151)
7. VS Donnenberg AD Donnenberg 2005 Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis J Clin Pharmacol 45 872 877 10.1177/0091270005276905 16027397 1:CAS:528:DC%2BD2MXpslSlsLo%3D (Pubitemid 41060226)
8. WJ Kim Y Kakehi H Kinoshita S Arao M Fukumoto O Yoshida 1996 Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP), glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney J Urol 156 506 511 10.1016/S0022-5347(01)65915-9 8683726 1:CAS:528:DyaK28XkvFartL8%3D (Pubitemid 126445369)
9. K Nishiyama T Shirahama A Yoshimura T Sumizawa T Furukawa M Ichikawa-Haraguchi S Akiyama Y Ohi 1993 Expression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas Cancer 71 3611 3619 10.1002/1097-0142(19930601)71:11<3611::AID-CNCR2820711124>3.0.CO;2-T 8098269 1:STN:280:DyaK3s3lvVOnsw%3D%3D (Pubitemid 23152673)
10. M Alvarez K Paull A Monks C Hose JS Lee J Weinstein M Grever S Bates T Fojo 1995 Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen J Clin Invest 95 2205 2214 10.1172/JCI117910 7738186 1:CAS:528:DyaK2MXltlWrtLk%3D
11. M Volm M Kastel J Mattern T Efferth 1993 Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas Cancer 71 3981 3987 10.1002/1097-0142(19930615)71:12<3981::AID-CNCR2820711231>3.0. CO;2-A 8099529 1:CAS:528:DyaK3sXmtVSktb8%3D (Pubitemid 23172981)
12. I Kausch H Jiang B Thode C Doehn S Kruger D Jocham 2005 Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma Eur Urol 47 703 709 10.1016/j.eururo.2004.11.013 15826766 1:CAS:528:DC%2BD2MXksFWku7c%3D (Pubitemid 40521925)
13. T Uchida JP Gao C Wang T Satoh I Itoh M Muramoto T Hyodo A Irie T Akahoshi SX Jiang T Kameya S Baba 2001 Antitumor effect of bcl-2 antisense phosphorothioate oligodeoxynucleotides on human renal-cell carcinoma cells in vitro and in mice Mol Urol 5 71 78 10.1089/109153601300177583 11690551 1:CAS:528:DC%2BD3MXkt1Cnt7c%3D (Pubitemid 32448699)
14. T Itoi K Yamana V Bilim K Takahashi F Tomita 2004 Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients Br J Cancer 90 200 205 10.1038/sj.bjc.6601454 14710230 1:CAS:528: DC%2BD2cXhtFKgtA%3D%3D (Pubitemid 38174962)
15. S Oudard C Levalois JM Andrieu J Bougaran P Validire N Thiounn MF Poupon E Fourme S Chevillard 2002 Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome Anticancer Res 22 121 128 12017273 1:CAS:528:DC%2BD38XktF2mtrk%3D (Pubitemid 34475285)
16. CT Lee EM Genega B Hutchinson PA Fearn MW Kattan P Russo VE Reuter 2003 Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors Urol Oncol 21 179 184 12810203 1:CAS:528:DC%2BD3sXks1Wks7s%3D
17. SP Vasavada AC Novick BR Williams 1998 P53, bcl-2, and Bax expression in renal cell carcinoma Urology 51 1057 1061 10.1016/S0090-4295(98)00132-0 9609655 1:STN:280:DyaK1c3ntVyiug%3D%3D (Pubitemid 28240877)
18. Y Tomita T Kawasaki V Bilim M Takeda K Takahashi 1996 Tetrapeptide DEVD-aldehyde or YVAD-chloromethylketone inhibits Fas/Apo-1(CD95)-mediated apoptosis in renal-cell-cancer cells Int J Cancer 68 132 135 10.1002/(SICI)1097-0215(19960927)68:1<132::AID-IJC23>3.0.CO;2-C 8895553 1:CAS:528:DyaK28XmsFygsrk%3D (Pubitemid 26354591)
19. R Maruyama K Yamana T Itoi N Hara V Bilim T Nishiyama K Takahashi Y Tomita 2006 Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma Br J Cancer 95 1244 1249 10.1038/sj.bjc.6603359 17031406 1:CAS:528:DC%2BD28XhtFChs7zP (Pubitemid 44658490)
20. I Hara S Hara H Miyake S Arakawa S Kamidono 2001 Bcl-2 modulates Fas-mediated apoptosis in human renal cell carcinoma cell lines Int J Oncol 18 1181 1185 11351249 1:CAS:528:DC%2BD3MXktlCjs70%3D
21. JD Kelly J Dai P Eschwege JS Goldberg BP Duggan KE Williamson NH Bander DM Nanus 2004 Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas Br J Cancer 91 164 170 10.1038/sj.bjc.6601895 15188008 1:CAS:528:DC%2BD2cXlt1Ckt7Y%3D (Pubitemid 39013061)
22. SP Xu GP Sun YX Shen WR Peng H Wang W Wei 2007 Synergistic effect of combining paeonol and cisplatin on apoptotic induction of human hepatoma cell lines Acta Pharmacol Sin 28 869 878 10.1111/j.1745-7254.2007.00564.x 17506946 1:CAS:528:DC%2BD2sXmsFenur8%3D (Pubitemid 46817434)
23. I Mlynarczuk-Bialy H Roeckmann U Kuckelkorn B Schmidt S Umbreen J Golab A Ludwig C Montag L Wiebusch C Hagemeier D Schadendorf PM Kloetzel U Seifert 2006 Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells Cancer Res 66 7598 7605 10.1158/0008-5472.CAN-05-2614 16885359 1:CAS:528:DC%2BD28XnsFyrurk%3D (Pubitemid 44289216)
24. PY Yeh SE Chuang KH Yeh YC Song CK Ea AL Cheng 2002 Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation Biochem Pharmacol 63 1423 1430 10.1016/S0006-2952(02) 00908-5 11996883 1:CAS:528:DC%2BD38XjsVSks7k%3D (Pubitemid 34457957)
25. KC Das CW White 1997 Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C J Biol Chem 272 14914 14920 10.1074/jbc.272.23.14914 9169462 1:CAS:528:DyaK2sXjslektLs%3D (Pubitemid 27251763)
26. J Guo UN Verma RB Gaynor EP Frenkel CR Becerra 2004 Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-kappaB p65 subunit Clin Cancer Res 10 3333 3341 10.1158/1078-0432.CCR-03-0366 15161687 1:CAS:528:DC%2BD2cXkt1Ghs7c%3D (Pubitemid 38685438)
27. AS Baldwin Jr 2001 Series introduction: the transcription factor NF-kappaB and human disease J Clin Invest 107 3 6 10.1172/JCI11891 11134170 1:CAS:528:DC%2BD3MXitVOhsQ%3D%3D
28. DJ Van Antwerp SJ Martin T Kafri DR Green IM Verma 1996 Suppression of TNF-alpha-induced apoptosis by NF-kappaB Science 274 787 789 10.1126/science.274.5288.787 8864120 (Pubitemid 26398260)
29. JC Cusack Jr R Liu AS Baldwin Jr 2000 Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation Cancer Res 60 2323 2330 10811101 1:CAS:528:DC%2BD3cXjtV2qsbo%3D (Pubitemid 30262414)
30. GH Liu SR Wang B Wang BH Kong 2006 Inhibition of nuclear factor-kappaB by an antioxidant enhances paclitaxel sensitivity in ovarian carcinoma cell line Int J Gynecol Cancer 16 1777 1782 10.1111/j.1525-1438.2006.00652.x 17009971 1:STN:280:DC%2BD28nhvVSiug%3D%3D (Pubitemid 44470035)
31. SE Chuang PY Yeh YS Lu GM Lai CM Liao M Gao AL Cheng 2002 Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells Biochem Pharmacol 63 1709 1716 10.1016/S0006-2952(02)00931-0 12007574 1:CAS:528:DC%2BD38XjsVSkt74%3D (Pubitemid 34458010)
32. F Chen V Castranova X Shi 2001 New insights into the role of nuclear factor-kappaB in cell growth regulation Am J Pathol 159 387 397 11485895 1:CAS:528:DC%2BD3MXms1WisLs%3D (Pubitemid 32751067)
33. MS Hayden S Ghosh 2004 Signaling to NF-kappaB Genes Dev 18 2195 2224 10.1101/gad.1228704 15371334 1:CAS:528:DC%2BD2cXnslCntbY%3D (Pubitemid 39209568)
34. M Karin Y Cao FR Greten ZW Li 2002 NF-kappaB in cancer: from innocent bystander to major culprit Nat Rev Cancer 2 301 310 10.1038/nrc780 12001991 1:CAS:528:DC%2BD38XivFGqt7k%3D (Pubitemid 37328783)
35. M Karin Y Ben-Neriah 2000 Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity Annu Rev Immunol 18 621 663 10.1146/annurev. immunol.18.1.621 10837071 1:CAS:528:DC%2BD3cXjs1Gmtro%3D (Pubitemid 30365393)
36. P Viatour MP Merville V Bours A Chariot 2005 Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation Trends Biochem Sci 30 43 52 10.1016/j.tibs.2004.11.009 15653325 1:CAS:528: DC%2BD2MXkslOkuw%3D%3D (Pubitemid 40093740)
37. F Thevenod JM Friedmann AD Katsen IA Hauser 2000 Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis J Biol Chem 275 1887 1896 10.1074/jbc.275.3.1887 10636889 1:CAS:528:DC%2BD3cXotFWqtA%3D%3D (Pubitemid 30060813)
38. CY Wang DC Guttridge MW Mayo AS Baldwin Jr 1999 NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis Mol Cell Biol 19 5923 5929 10454539 1:CAS:528:DyaK1MXlslSqurw%3D
39. CY Wang JC Cusack Jr R Liu AS Baldwin Jr 1999 Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB Nat Med 5 412 417 10.1038/10577 10202930 1:CAS:528:DyaK1MXksVCru7w%3D (Pubitemid 29180579)
40. S Mabuchi M Ohmichi Y Nishio T Hayasaka A Kimura T Ohta M Saito J Kawagoe K Takahashi N Yada-Hashimoto M Sakata T Motoyama H Kurachi K Tasaka Y Murata 2004 Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models J Biol Chem 279 23477 23485 10.1074/jbc.M313709200 15026414 1:CAS:528:DC%2BD2cXkt1GitL0%3D (Pubitemid 38685659)
41. M Venkatraman RJ Anto A Nair M Varghese D Karunagaran 2005 Biological and chemical inhibitors of NF-kappaB sensitize SiHa cells to cisplatin-induced apoptosis Mol Carcinog 44 51 59 10.1002/mc.20116 16044419 1:CAS:528: DC%2BD2MXpvFKku74%3D (Pubitemid 41216407)
42. G Otsuka T Nagaya K Saito M Mizuno J Yoshida H Seo 1999 Inhibition of nuclear factor-kappaB activation confers sensitivity to tumor necrosis factor-alpha by impairment of cell cycle progression in human glioma cells Cancer Res 59 4446 4452 10485496 1:CAS:528:DyaK1MXlvVSmsbs%3D (Pubitemid 29418767)
43. NM Patel S Nozaki NH Shortle P Bhat-Nakshatri TR Newton S Rice V Gelfanov SH Boswell RJ Goulet Jr GW Sledge Jr H Nakshatri 2000 Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide Oncogene 19 4159 4169 10.1038/sj.onc.1203768 10962577 1:CAS:528:DC%2BD3cXmsVKlsLk%3D
44. TK Lee RT Poon JY Wo S Ma XY Guan JN Myers P Altevogt AP Yuen 2007 Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model Cancer Res 67 8800 8809 10.1158/0008-5472.CAN-07- 0801 17875721 1:CAS:528:DC%2BD2sXhtVCit7jO (Pubitemid 47437456)
45. C Morais B Pat G Gobe DW Johnson H Healy 2006 Pyrrolidine dithiocarbamate exerts anti-proliferative and pro-apoptotic effects in renal cell carcinoma cell lines Nephrol Dial Transplant 21 3377 3388 10.1093/ndt/gfl543 16998220 1:CAS:528:DC%2BD2sXivFClug%3D%3D (Pubitemid 44817085)
46. JF Kerr GC Gobe CM Winterford BV Harmon 1995 Anatomical methods in cell death Methods Cell Biol 46 1 27 10.1016/S0091-679X(08)61921-4 7609651 1:STN:280:DyaK2Mzjtl2gsg%3D%3D
47. JF Kerr AH Wyllie AR Currie 1972 Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics Br J Cancer 26 239 257 4561027 1:STN:280:DyaE3s%2FgsFSksw%3D%3D
48. P Renard I Ernest A Houbion M Art H Le Calvez M Raes J Remacle 2001 Development of a sensitive multi-well colorimetric assay for active NFkappaB Nucleic Acids Res 29 E21 10.1093/nar/29.4.e21 11160941 1:STN:280: DC%2BD3M3msFagsQ%3D%3D
49. R Chinery JA Brockman MO Peeler Y Shyr RD Beauchamp RJ Coffey 1997 Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta Nat Med 3 1233 1241 10.1038/nm1197-1233 9359698 1:CAS:528:DyaK2sXntFanu7s%3D (Pubitemid 27508824)
50. C Nakanishi M Toi 2005 Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs Nat Rev Cancer 5 297 309 10.1038/nrc1588 15803156 1:CAS:528:DC%2BD2MXivVars7Y%3D (Pubitemid 40488635)
51. HW Lee SJ Park BK Choi HH Kim KO Nam BS Kwon 2002 4-1BB promotes the survival of CD8 + T lymphocytes by increasing expression of Bcl-xL and Bfl-1 J Immunol 169 4882 4888 12391199
52. SA Fox Kusmiaty SS Loh AM Dharmarajan MJ Garlepp 2005 Cisplatin and TNF-alpha downregulate transcription of Bcl-xL in murine malignant mesothelioma cells Biochem Biophys Res Commun 337 983 991 10.1016/j.bbrc.2005.09.147 16225850 1:CAS:528:DC%2BD2MXhtFCjs7rI (Pubitemid 41447009)
53. KV Floros H Thomadaki G Lallas N Katsaros M Talieri A Scorilas 2003 Cisplatin-induced apoptosis in HL-60 human promyelocytic leukemia cells: differential expression of BCL2 and novel apoptosis-related gene BCL2L12 Ann NY Acad Sci 1010 153 158 10.1196/annals.1299.025 15033711 1:CAS:528: DC%2BD2cXisFeksLk%3D (Pubitemid 38264966)
54. K Gunawardena LD Campbell AW Meikle 2005 Antiandrogen-like actions of an antioxidant on survivin, Bcl-2 and PSA in human prostate cancer cells Cancer Detect Prev 29 389 395 10.1016/j.cdp.2005.05.001 16139439 1:CAS:528: DC%2BD2MXhtFyiu7vL (Pubitemid 41267299)
55. S Ernest S Rajaraman J Megyesi EN Bello-Reuss 1997 Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney Nephron 77 284 289 10.1159/000190289 9375821 1:CAS:528:DyaK2sXntVajuro%3D (Pubitemid 27477685)
56. E Gamelin SD Mertins JT Regis L Mickley A Abati RA Worrell WM Linehan SE Bates 1999 Intrinsic drug resistance in primary and metastatic renal cell carcinoma J Urol 162 217 224 10.1097/00005392-199907000-00071 10379790 1:CAS:528:DyaK1MXktFenu7o%3D (Pubitemid 29420930)
57. C Mignogna S Staibano V Altieri G De Rosa G Pannone A Santoro R Zamparese M D'Armiento R Rocchetti E Mezza M Nasti V Strazzullo V Montanaro M Mascolo P Bufo 2006 Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis BMC Cancer 6 293 10.1186/1471-2407-6-293 17177989 1:CAS:528:DC%2BD2sXhtFajtbo%3D (Pubitemid 46454535)
58. T Efferth TA Dunn M Berlion H Langenbahn EW Pommerenke M Volm 1993 Reversal of inherent multidrug-resistance in primary human renal cell carcinoma cell cultures by S 9788 Anticancer Res 13 905 908 8102519 1:STN:280: DyaK3szls1Cqtg%3D%3D (Pubitemid 23247436)
59. AE Chapman LJ Goldstein 1995 Multiple drug resistance: biologic basis and clinical significance in renal-cell carcinoma Semin Oncol 22 17 28 7855615 1:STN:280:DyaK2M7lvVyqtg%3D%3D
60. GH Mickisch J Kossig G Keilhauer E Schlick RK Tschada PM Alken 1990 Effects of calcium antagonists in multidrug resistant primary human renal cell carcinomas Cancer Res 50 3670 3674 2340516 1:CAS:528:DyaK3cXkvFWjsb0%3D (Pubitemid 20194114)
61. M Volm EW Pommerenke T Efferth H Lohrke J Mattern 1991 Circumvention of multi-drug resistance in human kidney and kidney carcinoma in vitro Cancer 67 2484 2489 10.1002/1097-0142(19910515)67:10<2484::AID-CNCR2820671016>3.0. CO;2-I 1673084 1:STN:280:DyaK3M7pvFSisQ%3D%3D
62. BR Murphy SM Rynard KL Pennington W Grosh PJ Loehrer 1994 A phase II trial of vinblastine plus dipyridamole in advanced renal cell carcinoma. A Hoosier Oncology Group Study Am J Clin Oncol 17 10 13 10.1097/00000421- 199402000-00003 8311000 1:STN:280:DyaK2c7ksVGmtQ%3D%3D (Pubitemid 24062726)
63. YO Ilbey E Ozbek A Simsek M Cekmen A Otunctemur A Somay 2009 Chemoprotective effect of a nuclear factor-kB inhibitor, pyrrolidine dithiocarbamate, against cisplatin-induced testicular damage in rats J Androl 30 505 514 10.2164/jandrol.108.006270 19234314 1:CAS:528:DC%2BD1MXhtFCktbjN